Skip to content

A cross-sectional observational study of the relationship between a novel sympathetic nerve imaging tracer 18F-1799 on PET/CT and arrhythmia in patients with hypertrophic cardiomyopathy

A cross-sectional observational study of the relationship between a novel sympathetic nerve imaging tracer 18F-1799 on PET/CT and arrhythmia in patients with hypertrophic cardiomyopathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400087492
Enrollment
Unknown
Registered
2024-07-29
Start date
2024-07-29
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic Cardiomyopathy

Interventions

Hypertrophic cardiomyopathy patients with or without arrhythmias:None

Sponsors

Fuwai Hospital, CAMS&PUMC
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1) Patients aged 18 years and older. 2) Inpatients with a confirmed diagnosis of HCM in the cardiomyopathy department at Fuwai Hospital who consent to undergo 18F-1799 PET/CT imaging and sign the informed consent form. 3) Completion of comprehensive clinical assessments, including echocardiography, cardiac magnetic resonance imaging, functional testing, and biochemical blood tests. 4) Patients must undergo either a 24-hour Holter monitoring or a 12-lead electrocardiogram to evaluate the presence of arrhythmias based on the results.

Exclusion criteria

Exclusion criteria: 1) Patients unable to undergo PET/CT imaging. 2) Patients with a history of implanted ICD, prior surgical interventions such as Morrow surgery, alcohol septal ablation, or radiofrequency ablation aimed at relieving left ventricular outflow tract obstruction prior to enrollment. 3) Patients who have undergone arrhythmia ablation in the past. 4) Pregnant or breastfeeding women. 5) Patients with a history of myocardial infarction. 6) Patients presenting with symptoms or signs of heart failure (i.e., New York Heart Association classification III/IV, left ventricular ejection fraction [LVEF] < 50%, or other clinical evidence of heart failure).

Design outcomes

Primary

MeasureTime frame
18F-1799 uptake intensity, left ventricular TBRmax;

Countries

China

Contacts

Public ContactFang Wei

Fuwai Hospital, CAMS&PUMC

nuclearfw@126.com+86 136 7123 3077

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026